

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Liquid chromatography-high resolution mass spectrometry for broad-spectrum drug screening of dried blood spot as microsampling procedure

Authors: Joye T, Sidibé J, Déglon J, Karmime A, Sporkert F, Widmer C, Favrat B, Lescuyer P, Augsburger M, Thomas A

Journal: Analytica Chimica Acta

Year: 2019

Issue: 1063

Pages: 110-116

DOI: 10.1016/j.aca.2019.02.011

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Accepted Manuscript

Liquid Chromatography –High Resolution MS-based assay for broad-spectrum drug screening of dried blood spot as microsampling procedure

Timothée Joye, Jonathan Sidibe, Julien Déglon, Abderrahim Karmime, Frank Sporkert, Christèle Widmer, Bernard Favrat, Pierre Lescuyer, Marc Augsburger, Aurélien Thomas

PII: S0003-2670(19)30185-0

DOI: <https://doi.org/10.1016/j.aca.2019.02.011>

Reference: ACA 236575

To appear in: *Analytica Chimica Acta*


Received Date: 22 November 2018


Revised Date: 28 January 2019

Accepted Date: 4 February 2019

Please cite this article as: T. Joye, J. Sidibe, J. Déglon, A. Karmime, F. Sporkert, C. Widmer, B. Favrat, P. Lescuyer, M. Augsburger, A. Thomas, Liquid Chromatography –High Resolution MS-based assay for broad-spectrum drug screening of dried blood spot as microsampling procedure, *Analytica Chimica Acta*, <https://doi.org/10.1016/j.aca.2019.02.011>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





1 **Liquid Chromatography–High Resolution MS-based assay for broad-spectrum drug screening of dried blood spot as**
2 **microsampling procedure**

3
4 **Timothée Joye¹, Jonathan Sidibe¹, Julien Déglon¹, Abderrahim Karmime², Frank**
5 **Sporkert¹, Christèle Widmer¹, Bernard Favrat³, Pierre Lescuyer², Marc Augsburger¹,**
6 **Aurélien Thomas¹**

7 ¹Forensic Toxicology and chemistry unit, University centre of legal medicine, Lausanne-Geneva, Switzerland

8 ²Division of Laboratory Medicine, University Hospitals of Geneva, Switzerland

9 ³Unit of medicine and traffic psychology, University centre of legal medicine, Lausanne-Geneva, Switzerland

10

11 Corresponding author:

12 **Prof. Aurelien Thomas**

13 Unit of Toxicology, CURML

14 Vulliette 04 street,

15 1000 Lausanne 25 | Switzerland

16 Telephone: +41213143744

17 Fax: +41213147329

18 Aurelien.Thomas@chuv.ch

19

20 Nonstandard abbreviations: STA, systematic toxicological analysis; GUS, general unknown screening; LC,
21 liquid chromatography; HRMS, high resolution mass spectrometry; DDA, data-dependent acquisition; DBS,
22 dried blood spot; DMS, dried matrix spot; MRM, multiple reaction monitoring; LOI, limit of identification;
23 LOD, limit of detection; DIA, data-independent acquisition; SWATH, sequential window acquisition of all
24 theoretical fragment-ion spectra; MSX, multiplexed.

25 Abstract

26 **Background:** Hyphenation of liquid chromatography (LC) with high-resolution mass spectrometry (HRMS)
27 offers the potential to develop broad-spectrum screening procedures from low volumes of biological matrices. In
28 parallel, dried blood spot (DBS) has become a valuable tool in the bioanalysis landscape to overcome
29 conventional blood collection issues. Herein, we demonstrated the applicability of DBS as micro-sampling
30 procedure for broad-spectrum toxicological screening.

31 **Methods:** A method was developed on a HRMS system in data dependant acquisition (DDA) mode using an
32 extensive inclusion list to promote collection of relevant data. 104 real toxicology cases were analysed, and the
33 results were cross-validated with one published and one commercial screening procedures. Quantitative MRM
34 analyses on a triple quadrupole instrument were also performed on identified substances as a complementary
35 confirmation procedure.

36 **Results:** The method showed limits of identification (LOIs) in appropriateness with therapeutic ranges for all the
37 classes of interest. Applying the three screening approaches on 104 real cases, 271 identifications were
38 performed including 14 and 6 classes of prescribed and illicit drugs, respectively. Among the detected
39 substances, 23% were only detected by the proposed method. Based on confirmatory analyses, we demonstrated
40 that the use of blood micro-samples did not impair the sensitivity allowing more identifications in the low
41 concentration ranges.

42 **Conclusion:** A LC-HRMS assay was successfully developed for toxicological screening of blood microsamples
43 demonstrating a high identification power at low concentration ranges. The validation procedure and the analysis
44 of real cases demonstrated the potential of this assay by supplementing screening approaches of reference.

45 1. Introduction

46 Systematic toxicological analysis (STA) is of primary importance in both clinical and forensic toxicology. It
47 generally consists of a combination of analytical strategies including immunoassays, and chromatography
48 hyphenated to mass spectrometry [1-3]. In STA, orientation tests and preliminary screening are performed,
49 which can be referred as general unknown screening (GUS)[4]. The goal of this procedure is to conclude in a
50 precise and unambiguous way if any substance of toxicological interest has been consumed or not prior
51 confirmatory quantitative analysis[5, 6]. This challenging task depends on the biological matrix, sample
52 preparation, analytical technique, and the compound database.

53 Currently, liquid chromatography (LC) hyphenated with mass-spectrometry (MS) is partially replacing gas
54 chromatography (GC)-MS approaches regarding GUS in blood and urine and numerous applications have been
55 mentioned[6, 7].

56 The introduction of high-resolution MS (HRMS) analyser and especially Orbitrap technology, gives the
57 opportunity to investigate several analytical strategies including full scan data dependent acquisition (DDA) [8-
58 10]. The latest generation of Fourier transform MS, routinely reaches mass resolution above 70,000 at 1-ppm
59 mass accuracy and high spectral resolution capacities. Continual improvement of scan rate frequencies and
60 dynamic range lead to instruments particularly adapted for large-scale comprehensive screening in complex
61 matrices [11-13]. The increased mass accuracy allows to facilitate identification by reducing the number of
62 possible chemical formulas [6]. Lastly, this technology offers fast positive/negative polarity switching at high
63 scan rates allowing the simultaneous analysis of a wide range of substances [14]. Therefore, HR full-scan
64 methods are very suitable for the development of large-scale screening procedure and especially for drug
65 screening [3, 15]. By improving the mass resolution power, HRMS increases the selectivity, therefore reducing
66 the potential interferences [10]. The associated improvement in terms of sensitivity could allow to reduce the
67 volume of biological matrices used for the screening procedure.

68 Currently, urine is the gold standard regarding screening approaches since its sampling is simple and non-
69 invasive. Moreover, urine is relatively poor in proteins and lipids that could interfere with the signal of the
70 analytes and concentrate most analytes reducing potential sensitivity issues [16]. Compared to urine, blood
71 sampling presents significant advantages since it is difficult to counterfeit, and the toxicological interpretation of
72 concentration is facilitated making it the gold standard for confirmatory analysis [17]. However, blood sampling
73 induces several logistical and analytical issues. Indeed, classical venepuncture is invasive, requires special

74 logistic and medical supervision [18]. In addition, in some situations, especially concerning problematic and
75 vulnerable patient population, only limited volumes of blood are available [19]. To bypass those issues, the use
76 of cellulose paper cards has been mentioned [20]. The first use of dried blood spot (DBS) has been reported by
77 Guthrie and Susie more than 50 years ago, for paediatric purpose [21]. Among advantages, DBS sampling
78 requires the collection of a small volume of blood (5-10 μ L). Moreover, it is performed by finger or heel
79 pricking that can be performed by a technician or by the patient himself after minimal training in a non-hospital
80 environment [22]. The adsorption and drying of blood on a solid phase makes analytes less reactive, leading to
81 facilitated shipment and storage and reducing the costs [23]. Lastly, during blood adsorption and drying most
82 pathogenic agents are deactivated leading to a safer handling of samples [24].

83 Various applications of detection of drugs using dried matrix spots (DMS) [14, 27] and especially DBS sampling
84 have already been presented [7, 23, 28, 29]. For instance, analyses on DBS have been used for both quantitative
85 (quantification of benzodiazepines) [22] and screening approaches either for doping screening [7] or for
86 toxicological analyses using a targeted strategy [30]. Indeed, DBS presents several advantages for MS-based
87 analyses since samples preparation can be accelerated and facilitated. Moreover, using organic solvents, lipids
88 and proteins are mostly being retained on the paper-card allowing the reduction of matrix effects, making this
89 sampling support particularly adapted to MS-based strategies [22, 31-33]. We previously demonstrated the
90 potential of DBS for targeted drug screening using a multiple reaction monitoring (MRM)-DDA approach [30].
91 In the present study, we extend the screening capabilities from DBS samples using the analytical advantages
92 brought by the HRMS, notably by broadening the number of possible identifications. In this way, a full-scan-
93 DDA LC-HRMS method was developed using an inclusion list of more than 1000 compounds including all
94 classes of interest. The developed assay requires limited sample preparation and allows the identification of a
95 wide-range of compounds. Representative substances were tested for the chromatographic and MS parameters
96 optimisation including non-exhaustively amphetamines, benzodiazepines, cocaine, antidepressants, neuroleptics,
97 opioids, NPS, anticonvulsants, and THC-COOH. In a second time, a subset of 30 substances was used for the
98 determination of the limits of identification (LOIs). This method was then assessed using 104 behavioural
99 toxicology real cases. The results were cross-validated by two published screening methods used in routine [30,
100 34]. Confirmation assessment were also performed using quantitative analysis as a complementary approach to
101 evaluate the efficiency of the developed routine screening method presented herein.

102 2. Methods

103 2.1 Standards and reagents

104 Water, methanol, formic acid (FA), dichloromethane, hydrochloric acid, hexane and ethyl acetate UPLC,
105 potassium and sodium chloride, boric acid, and ammonium formate were purchased from Biosolve, Sigma-
106 Aldrich or Merck. Drug standards were purchased at 1 mg/ml either from Cerilliant or Lipomed. Blank,
107 lyophilized whole blood for method development was purchased from ACQ Science. Protein saver cards for
108 DBS sampling were purchased from Whatman. Whole blood external quality control (EQC) PM100 for pain
109 management and drug of abuse (DoA-I VB low) were purchased from UTAK® (Supplemental Table 1) and
110 Medidrug® (Supplemental Table 2) respectively.

111 2.2 Sample preparation

112 For method development, blank whole blood was spiked with drugs at different concentrations (1, 5, 10, 20 and
113 50 ng mL⁻¹). Methanolic standard were evaporated under a nitrogen flow at room temperature before
114 reconstitution in blood. Then 10 µL were deposited on a DBS filter paper card. Drugs were tested for limits of
115 identification and detection determination, chromatography and identification optimisation including
116 benzodiazepines, NPS, neuroleptics, opioids, antidepressants, synthetic cannabinoids, amphetamines,
117 anticonvulsant, cocaine and cannabinoids. A double extraction process on DBS was developed. One spot was
118 extracted using 100 µL of methanol and mixed for 2 minutes. A second spot was extracted using 100 µL of
119 borate buffer 0.5 M pH 9.5, after mixing for 2 minutes, 300 µL of DCM: Hexane: Ethyl Acetate (5:4:1) were
120 added. This second spot was then centrifugated and the organic phase was mixed with the 100 µL of methanol
121 extract from the first extraction in a new tube. Organic solvents were then evaporated at room temperature using
122 a nitrogen flow, and samples were reconstituted with 50 µL of water.

123 2.3 LC-HRMS method

124 All samples were injected (10 µL injection volume) using partial loop injection mode on the LC-Q Exactive Plus
125 system (Thermo Scientific, Bremen, Germany). Chromatographic separation using a Thermo Scientific Ultimate
126 3000 LC system with a Phenomenex 2.6 µm C18 (2.1 X 50 mm) maintained at 45°C. Mobile phase A consisted
127 of ammonium formate 10 mM pH 3.3 and mobile phase B of MeOH with 0.1 % FA. Phase B was ramped
128 linearly from 2 to 98% over 6 minutes. The column was washed at 98 % of B for 3 minutes, followed by a 3.5
129 minutes reequilibration at 2 % of B. The LC was coupled to the MS via a heated ESI source associated with a Q
130 Exactive Plus operating in full-scan DDMS² positive polarity with a Tsim DDMS² negative polarity switching

131 between min 6 and 7 only for the specific detection of THC-COOH (supplemental Figure 1A). The ionisation
132 spray voltage was set to 3 kV, sheath gas flowrate was set to 40 and auxiliary gas flowrate to 10 (both in
133 arbitrary unit). HCD fragmentation was performed with an inclusion list containing 1008 compounds using NCE
134 at 70 eV in positive polarity and 30 eV in negative polarity. No dynamic exclusion was set. Resolution was set to
135 70'000 for the full scan experiment in positive polarity while it was set to 17'500 during the polarity switching
136 and the fragmentation experiments.

137 2.3 Data analysis

138 Data analysis was performed using TraceFinder (Thermo Scientific) and a database containing more than 1000
139 compounds (Supplemental Table 3). Four criteria were used for substance identification including the mass over
140 charge ration (m/z), the isotopic pattern (IP), the retention time (RT) and the library search (LS) based on the
141 fragmentation spectra comparison. Peak detection was based on a S/N threshold of 10 with a 10 ppm tolerance.
142 Library search was considered successful with a match greater or equal to 50 %. IP needed to fit over 65%
143 allowing 10 ppm mass and 20% intensity deviations and RT was considered with a 30 seconds precision.
144 Substances identification was still possible if either the RT or the LS do not match..

145 2.4 Method evaluation

146 LOIs were measured using a list of 30 substances including most classes of interest (Table 1). LOIs were
147 evaluated by injecting 5 spiked replicates at 1, 5, 10 and 20 ng mL⁻¹. To minimise the risk of false negative and
148 as described elsewhere, LOI was considered as the lowest concentration at which the substances are detected and
149 identified in all five replicates based on the four criteria previously described [35, 36]. Limits of detection
150 (LODs) were defined as the minimal concentration at which at least the accurate mass precursor ion is detectable
151 [14]. Method reproducibility and instrument response were then evaluated using whole blood controls EQC
152 UTAK® pain management PM 100 (Supplemental Table 1) and the lowest concentration Medidrug® for drug of
153 abuse (Supplemental Table 2) spotted on a filter paper card. Each QC was injected at the beginning and the end
154 of each sequence. A QC was considered acceptable when all its substances targeted by the method were
155 identified regarding the four criteria. Selectivity was assessed by injecting ten different blood samples spotted on
156 DBS. Matrix effect (ME) and recovery (RE) was evaluated according to the approach described by Matuszewski
157 et al [37], three sample sets were prepared including 30 representative substances (Table 1). Five different blank
158 blood sample or neat standard were spiked with those substances at two concentration levels (20 and 200 ng mL⁻¹).
159 Sample set 1 represented neat standards. Sample set 2 blank blood matrix spots spiked after extraction while
160 sample set 3 represented blank blood matrix spiked and spotted before extraction.

161 To evaluate and confirm the efficiency of the whole process, 104 samples from forensic and clinical toxicology
162 were analysed. Those samples were also analysed by two other routine LC-MS methods. The first one was
163 developed for forensic toxicology using one 10 μ L DBS sample. The spot was introduced into a vial with 100
164 μ L of methanol and injected on the LC-MS/MS system. The analysis was performed on a Qtrap® 5500 (AB,
165 Sciex) working in targeted multiple reaction monitoring (MRM)-DDA. The chromatography was performed both
166 on a reverse phase (RP) and a Hilic column in parallel [30]. The second one was developed for clinical
167 toxicology on a Toxtyper LC-IT-MS System (Brucker). Sample preparation was based on alkaline liquid/liquid
168 extraction with sodium carbonate 1M and butyl acetate from 500 μ L of whole blood. The method was based on
169 low-resolution ion trap technology after a standard RP chromatographic separation. The MS experiment was
170 performed in full-scan DDA with continuous positive/negative ionisation mode switching [34]. Identifications
171 performed by the 3 methods have been compared as a cross-validation step. The detection of a substance was
172 confirmed either if it was detected by at least two of the assessed methods or if its identification was
173 unambiguous. Carryover was evaluated by injecting a methanol sample after each analysed blood sample and by
174 analysing 10 different blank whole blood samples after the injection of the 104 real cases. In addition, sensitivity
175 assessment and identification confirmation has been processed using quantitative analysis.

176 3. Results and discussion

177 3.1 Sample preparation

178 DBS provides several well-known advantages toward sample collection. Moreover, the use of blood micro-
179 sampling was described as a promising technique to simplify sample preparation prior to the analysis and reduce
180 the solvent volumes [30, 38]. Using only two 10 μ L spots, a limited sample preparation was sufficient to
181 sensitively detect all the classes of drugs of interest in their therapeutic or legal range. The development of such
182 micro-sampling strategies presents an alternative for blood collection in non-hospital environment facilitating
183 potential large cohort studies [25]. In addition, the combination of simplified sampling with large-scale
184 adaptative screening approaches could be a public health asset for monitoring habits of consumption and for
185 targeted prevention. For instance, the emergence of quickly evolving novel psychoactive substances (NPS)
186 emphasize the risk for the population requiring large-scale adaptative analytical strategies [26].

187

188 The method was validated according to the recommendations regarding qualitative approaches [39, 40]. Water
189 was selected as reconstitution solvent based on a compromise between specificity for a maximum of compounds

190 with different physico-chemical properties and chromatography. Selectivity was investigated using ten blank
191 blood samples spotted on DBS and ten clean filter paper cards. No effects were observed extracting and
192 analysing clean paper spots, suggesting that no substances were released from the paper during the extraction
193 procedure. No interfering compounds impaired the detection of the substances of interest analysing blank DBS
194 samples. The systematic injection of a blank methanol after every analysed samples did not revealed carry-over
195 even after injection of the highest EQC level (i.e. no remaining peaks were observed in the injected methanol for
196 those exact masses). This was confirmed from real cases analyses since no carryover was observed after the
197 injection of samples containing high concentrations of benzoylecgonine (2900 ng mL⁻¹), tramadol (1400 ng mL⁻¹)
198 ¹) or zolpidem (1200 ng mL⁻¹). The RE and ME results for the DBS extraction process are depicted in Table 1.
199 The mean ME at 20 ng mL⁻¹ was 34 % ranging from -53 % to 319 % and 13 % at 200 ng mL⁻¹ ranging from -42
200 % to 178 %. RE was ranging from 36 % to 121 % for respectively benzoylecgonine and cocaine at 20 ng mL⁻¹
201 and from 22 to 71 % for respectively methamphetamine and fluoxetine at 200 ng/ml. Maximal ion suppression
202 was observed for THC-COOH while maximal ion enhancement was observed for fluoxetine. Those ME and RE
203 values are in accordance to previous studies [7, 32, 41]

204 3.2 Detection and identification

205 Despite several advantages provided by DBS, the use of micro-sampling requires highly sensitive instruments.
206 LODs and LOIs for the 30 model compounds are listed in Table 1. As described above, LOI was defined as the
207 lowest concentration where at least 3 of the 4 identification criteria (m/z, IP, RT and LS) were fulfilled while
208 LOD was based only on the parent peak detection explaining the slight differences between those parameters
209 [11, 14]. LOIs were determined to be equal or lower than 20 ng mL⁻¹ for all the 30 substances tested including 11
210 different classes of molecules, which was the initial goal. LOI was measured at 20 ng mL⁻¹ for one substance
211 (Gabapentin), while 4 substances have been successfully identified in all 5 replicates at 5 and 10 ng mL⁻¹. For
212 most of the tested substances (63 %) the LOI was assessed to be 1 ng mL⁻¹. Determined LOIs were confirmed by
213 the identification of all substances in the lowest EQC levels (Supplemental table 1 and 2). LOD and LOI were
214 found to be in adequation with the therapeutic ranges [42] or the legal thresholds according to the Swiss
215 legislation [43]. Regarding identification, parameters were selected to maximise the method efficiency and
216 reduce the potential number of false negatives. Further investigation by the operator is required when either the
217 library spectra or the retention time does not match. The use of such an approach allows identifications by post-
218 processing after database adjustments. By relaxing those identification criteria, the sensitivity is increased

219 leading to a higher risk of false positive identification. Therefore, a careful data handling is performed by the
220 operator to assess whether it is a true or false positive.

221

222 3.3 Application of the method on real cases

223 From the three different screening methods, 271 identifications were validated among the 104 clinical and
224 forensic toxicology blood samples (Supplemental Table 4). In total, six classes of illicit drugs (amphetamines,
225 cannabinoids, opioids, NPS and LSD) and 14 classes of prescribed drugs including non-exhaustively antifungals,
226 antimalarials, antidiabetics, antihistaminic, beta-blockers, or proton-pump inhibitors were detected. The
227 prescribed drugs were summarized as five classes of prescribed drugs (benzodiazepines, neuroleptics,
228 antidepressants, anaesthetics/analgesics and other drugs) for better representation. In 24 cases, no compound was
229 detected and identified while in the 80 other cases, a total of 79 different substances were confirmed. The
230 targeted MRM-DDA approach on DBS allowed the identification of 57 % of the substances while using the
231 Toxtyper® on whole blood this number has increased to 72 %. Using the HRMS-DDA full-scan approach, 99 %
232 of the “hits” were identified on DBS confirming the efficiency of the developed method (Figure 1 A). As
233 expected THC-COOH was the most detected substance being present in more than 46 % of all the cases (104)
234 (Figure 2). Without considering THC-COOH which is targeted only by the HRMS-DDA approach, the
235 percentage of identification respectively increases to 87% and 69 % for the Toxtyper and the MRM-DDA.
236 Cocaine, benzodiazepines and amphetamines were respectively detected in 19 %, 17 % and 8 % of the cases
237 (Figure 2). A total of 18% of the cases were containing either an anaesthetic or an analgesic including ketamine
238 or lidocaine. Other drugs were responsible for 13 % of all identifications while one case of NPS (mephedrone)
239 and one containing LSD were listed. The differences between the percentage of detected substances and the
240 occurrence in cases (reaching more than 170%) can be explained by the concomitant consumption of 2 or more
241 drugs (55 % of the positive cases). Cannabinoids (represented only by THC-COOH) were the most single-drug
242 consumed (80% of the cases positive to only one substance). Quantitative confirmations were performed on
243 qualitatively identified substances targeted by the 3 methods. As confirmed by the quantitative results, the
244 number of identifications using HRMS is increased in the lowest concentration ranges (see Figure 1B). As an
245 illustration, at concentrations between 0 to 10 ng mL⁻¹, 40 % and 50 % of the confirmed substances detected by
246 the HRMS-DDA procedure were respectively not identified by the MRM-DDA and the Toxtyper approaches. At
247 the opposite, the 3 methods were able to detect all the compounds of interest from concentrations higher than
248 200 ng mL⁻¹. The HRMS improvement in terms of selectivity also results in an increase of sensitivity for full-

249 scan approaches allowing to work with blood micro-samples. Nevertheless, the demonstrated gain of sensitivity
250 also results in higher risks of false positive. Peak area thresholds have been implemented for well-ionised
251 substances and classic contaminants such as cocaine or methadone.

252 Due to the number of substances to cover and the diversity of physico-chemical properties, the development of
253 an unbiased and sensitive screening procedure is a difficult task ³⁰. Current HRMS technologies offer the
254 possibility to use either DDA [41] or data independent acquisition (DIA) including sequential window
255 acquisition of all theoretical fragment-ion spectra (SWATH) [44, 45] or multiplexed (MSX) [46]. A recent study
256 demonstrated the interest of SWATH in comparison to conventional DDA for the analysis of coeluting
257 substances in complex matrices [47]. Despite the theoretical advantages of DIA strategies for toxicological
258 screening, these approaches generate complex composite MS/MS spectra, which may hinder the identification of
259 substances in the low concentration ranges. These issues would be overcome with the development of more
260 efficient search algorithms and deconvolution processes for DIA routine applications [48].

261 Unlike DIA approaches, a limiting factor of DDA using intensity threshold as the main criteria would be the
262 cycle time for fragmentation in case of coelution which can lead to prioritize MS/MS acquisitions of matrix
263 interferences over pertinent compounds [47]. Even if DDA limits retrospective data evaluation because only
264 known precursors are selected for fragmentation, by producing better fragmentation spectra than DIA [47, 49], the
265 use of DDA with a large inclusion list (i.e. more than 1000 substances as demonstrated herein) thus allow the
266 instrument to spend time only on collecting relevant data. Besides, the inclusion list flexibility allows the fast
267 and easy adaptation to any new substances increasing the method identification power.

268 4. Conclusion

269 In summary, a large-scale HRMS toxicology screening strategy was developed on DBS samples. The method
270 operating in full-scan DDA using an inclusion list of more than 1000 compounds showed a high identification
271 power in which new substances can easily be implemented. The method was cross-validated with one published
272 and one commercial screening procedures. Confirmation quantitative analyses on identified compounds have
273 demonstrated that despite the use of blood micro-samples the sensitivity was not impaired providing several
274 advantages. Regarding the importance of screening procedures within the STA, rapid and comprehensive GUS
275 tools are necessary and should be proposed. The hyphenation of DBS with HRMS might be an attractive solution
276 combining a friendly sampling process with highly selective and sensitive MS-based detection. This method that
277 was validated [39] and implemented for its use in routine opens notably new toxicological perspectives towards

278 population monitoring in non-hospital environment. In a near future, the development of online shared libraries
279 such as m/z cloud and bioinformatic tools should allow to broaden the number of efficient large-scale screening
280 strategies especially regarding non-targeted approaches.

281 5. References

282

- 283 [1] F. Versace, J. Deglon, P. Mangin, C. Staub, Application of direct-infusion ESI-MS/MS for toxicological
284 screening, *Bioanalysis*, 6 (2014) 2043-2055.
- 285 [2] F. Versace, F. Sporkert, P. Mangin, C. Staub, Rapid sample pre-treatment prior to GC-MS and GC-MS/MS
286 urinary toxicological screening, *Talanta*, 101 (2012) 299-306.
- 287 [3] A.H. Wu, J. Colby, High-Resolution Mass Spectrometry for Untargeted Drug Screening, *Methods Mol Biol*,
288 1383 (2016) 153-166.
- 289 [4] L. Roche, J. Pinguet, P. Herviou, F. Libert, C. Chenaf, A. Eschalier, N. Authier, D. Richard, Fully automated
290 semi-quantitative toxicological screening in three biological matrices using turbulent flow chromatography/high
291 resolution mass spectrometry, *Clin Chim Acta*, 455 (2016) 46-54.
- 292 [5] M.R. Meyer, A.G. Helfer, H.H. Maurer, Current position of high-resolution MS for drug quantification in
293 clinical & forensic toxicology, *Bioanalysis*, 6 (2014) 2275-2284.
- 294 [6] E. Jagerdeo, J.E. Schaff, Rapid screening for drugs of abuse in biological fluids by ultra high performance
295 liquid chromatography/Orbitrap mass spectrometry, *J Chromatogr B Analyt Technol Biomed Life Sci*, 1027
296 (2016) 11-18.
- 297 [7] A. Thomas, H. Geyer, W. Schanzer, C. Crone, M. Kellmann, T. Moehring, M. Thevis, Sensitive
298 determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop
299 quadrupole/Orbitrap mass spectrometer, *Anal Bioanal Chem*, 403 (2012) 1279-1289.
- 300 [8] W. Jia, X. Chu, J. Chang, P.G. Wang, Y. Chen, F. Zhang, High-throughput untargeted screening of
301 veterinary drug residues and metabolites in tilapia using high resolution orbitrap mass spectrometry, *Anal Chim*
302 *Acta*, 957 (2017) 29-39.
- 303 [9] S.B. Turnipseed, J.M. Storey, J.J. Lohne, W.C. Andersen, R. Burger, A.S. Johnson, M.R. Madson, Wide-
304 Scope Screening Method for Multiclass Veterinary Drug Residues in Fish, Shrimp, and Eel Using Liquid
305 Chromatography-Quadrupole High-Resolution Mass Spectrometry, *J Agric Food Chem*, 65 (2017) 7252-7267.
- 306 [10] N.S. Chindarkar, M.R. Wakefield, J.A. Stone, R.L. Fitzgerald, Liquid chromatography high-resolution TOF
307 analysis: investigation of MSE for broad-spectrum drug screening, *Clin Chem*, 60 (2014) 1115-1125.
- 308 [11] A.G. Helfer, J.A. Michely, A.A. Weber, M.R. Meyer, H.H. Maurer, Liquid chromatography-high
309 resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs
310 and their metabolites in blood plasma, *Anal Chim Acta*, 965 (2017) 83-95.
- 311 [12] A. Makarov, E. Denisov, O. Lange, S. Horning, Dynamic range of mass accuracy in LTQ Orbitrap hybrid
312 mass spectrometer, *J Am Soc Mass Spectrom*, 17 (2006) 977-982.
- 313 [13] J. Ivanisevic, A. Thomas, *Metabolomics as a Tool to Understand Pathophysiological Processes*, *Methods*
314 *Mol Biol*, 1730 (2018) 3-28.
- 315 [14] A.G. Helfer, J.A. Michely, A.A. Weber, M.R. Meyer, H.H. Maurer, Orbitrap technology for comprehensive
316 metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening -
317 exemplified for cardiovascular drugs, *Anal Chim Acta*, 891 (2015) 221-233.
- 318 [15] K.M. Ostermann, A. Luf, N.M. Lutsch, R. Dieplinger, T.P. Mechtler, T.F. Metz, R. Schmid, D.C. Kasper,
319 MALDI Orbitrap mass spectrometry for fast and simplified analysis of novel street and designer drugs, *Clinica*
320 *Chimica Acta*, 433 (2014) 254-258.
- 321 [16] M. Sundstrom, A. Pelander, I. Ojanpera, Comparison between drug screening by immunoassay and ultra-
322 high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine,
323 *Drug Test Anal*, 7 (2015) 420-427.
- 324 [17] G. Skopp, Preanalytic aspects in postmortem toxicology, *Forensic Sci Int*, 142 (2004) 75-100.
- 325 [18] J.D. Freeman, L.M. Rosman, J.D. Ratcliff, P.T. Strickland, D.R. Graham, E.K. Silbergeld, State of the
326 Science in Dried Blood Spots, *Clin Chem*, 64 (2018) 656-679.
- 327 [19] C.P. Stove, A.S. Ingels, P.M. De Kesel, W.E. Lambert, Dried blood spots in toxicology: from the cradle to
328 the grave?, *Crit Rev Toxicol*, 42 (2012) 230-243.
- 329 [20] M. Bosilkovska, C. Samer, J. Deglon, A. Thomas, B. Walder, J. Desmeules, Y. Daali, Evaluation of Mutual
330 Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood
331 Sampling Method, *Basic Clin Pharmacol Toxicol*, 119 (2016) 284-290.
- 332 [21] R. Guthrie, A. Susi, A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of
333 Newborn Infants, *Pediatrics*, 32 (1963) 338-343.
- 334 [22] J. Deglon, F. Versace, E. Lauer, C. Widmer, P. Mangin, A. Thomas, C. Staub, Rapid LC-MS/MS
335 quantification of the major benzodiazepines and their metabolites on dried blood spots using a simple and cost-
336 effective sample pretreatment, *Bioanalysis*, 4 (2012) 1337-1350.
- 337 [23] M. Wagner, D. Tonoli, E. Varesio, G. Hopfgartner, The use of mass spectrometry to analyze dried blood
338 spots, *Mass Spectrom Rev*, 35 (2016) 361-438.

- 339 [24] S.P. Parker, W.D. Cubitt, The use of the dried blood spot sample in epidemiological studies, *J Clin Pathol*,
340 52 (1999) 633-639.
- 341 [25] J. Deglon, L.A. Leuthold, A. Thomas, Potential missing steps for a wide use of dried matrix spots in
342 biomedical analysis, *Bioanalysis*, (2015).
- 343 [26] P. Adamowicz, B. Tokarczyk, Simple and rapid screening procedure for 143 new psychoactive substances
344 by liquid chromatography-tandem mass spectrometry, *Drug Test Anal*, 8 (2016) 652-667.
- 345 [27] J.A. Michely, M.R. Meyer, H.H. Maurer, Power of Orbitrap-based LC-high resolution-MS/MS for
346 comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot
347 cleavage in comparison to established LC-MSn or GC-MS procedures, *Drug Test Anal*, (2017).
- 348 [28] L. Tretzel, A. Thomas, T. Piper, M. Hedeland, H. Geyer, W. Schanzer, M. Thevis, Fully automated
349 determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-
350 MS/MS approach for sports drug testing, *J Pharm Biomed Anal*, 123 (2016) 132-140.
- 351 [29] H. Lee, Y. Park, J. Jo, S. In, Y. Park, E. Kim, J. Pyo, S. Choe, Analysis of benzodiazepines and their
352 metabolites using DBS cards and LC-MS/MS, *Forensic Sci Int*, 255 (2015) 137-145.
- 353 [30] F. Versace, J. Deglon, E. Lauer, P. Mangin, C. Staub, Automated DBS Extraction Prior to Hilic/RP LC-
354 M/MS Target Screening of Drugs, *Chromatographia*, 76 (2013) 1281-1293.
- 355 [31] R. Zakaria, K.J. Allen, J.J. Koplín, P. Roche, R.F. Greaves, Advantages and Challenges of Dried Blood
356 Spot Analysis by Mass Spectrometry Across the Total Testing Process, *EJIFCC*, 27 (2016) 288-317.
- 357 [32] T. Gaissmaier, M. Siebenhaar, V. Todorova, V. Hullen, C. Hopf, Therapeutic drug monitoring in dried
358 blood spots using liquid microjunction surface sampling and high resolution mass spectrometry, *Analyst*, 141
359 (2016) 892-901.
- 360 [33] P. Abu-Rabie, N. Spooner, B.Z. Chowdhry, F.S. Pullen, DBS direct elution: optimizing performance in
361 high-throughput quantitative LC-MS/MS analysis, *Bioanalysis*, 7 (2015) 2003-2017.
- 362 [34] M. Ott, K. Berbalk, T. Plecko, E. Wieland, M. Shipkova, Detection of drugs of abuse in urine using the
363 Bruker Toxtyper™: Experiences in a routine clinical laboratory setting, *Clinical Mass Spectrometry*, 4-5 (2017)
364 11-18.
- 365 [35] N. Fabresse, I.A. Larabi, T. Stratton, R. Mistrik, G. Pfau, G. Lorin de la Grandmaison, I. Etting, S. Grassin
366 Delyle, J.C. Alvarez, Development of a sensitive untargeted LC-HRMS screening devoted to hair analysis
367 through a shared MS2 spectra database: a step towards early detection of new psychoactive substances, *Drug*
368 *Test Anal*, (2018).
- 369 [36] V. Viette, D. Guillarme, R. Mylonas, Y. Mauron, M. Fathi, S. Rudaz, D. Hochstrasser, J.L. Veuthey, A
370 multi-target screening analysis in human plasma using fast liquid chromatography-hybrid tandem mass
371 spectrometry (Part I), *Clin Biochem*, 44 (2011) 32-44.
- 372 [37] B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng, Strategies for the assessment of matrix effect in
373 quantitative bioanalytical methods based on HPLC-MS/MS, *Anal Chem*, 75 (2003) 3019-3030.
- 374 [38] A. Thomas, J. Deglon, T. Steimer, P. Mangin, Y. Daali, C. Staub, On-line desorption of dried blood spots
375 coupled to hydrophilic interaction/reversed-phase LC/MS/MS system for the simultaneous analysis of drugs and
376 their polar metabolites, *J Sep Sci*, 33 (2010) 873-879.
- 377 [39] F.T. Peters, O.H. Drummer, F. Musshoff, Validation of new methods, *Forensic Sci Int*, 165 (2007) 216-224.
- 378 [40] K.L. Lynch, CLSI C62-A: A New Standard for Clinical Mass Spectrometry, *Clin Chem*, 62 (2016) 24-29.
- 379 [41] K.L. Thoren, J.M. Colby, S.B. Shugarts, A.H. Wu, K.L. Lynch, Comparison of Information-Dependent
380 Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for
381 Broad-Spectrum Drug Screening, *Clin Chem*, 62 (2016) 170-178.
- 382 [42] M. Schulz, S. Iwersen-Bergmann, H. Andresen, A. Schmoltdt, Therapeutic and toxic blood concentrations of
383 nearly 1,000 drugs and other xenobiotics, *Crit Care*, 16 (2012) R136.
- 384 [43] Ordonnance de l'OFROU concernant l'ordonnance sur le contrôle de la circulation routière, art. 34 (2008).
- 385 [44] K. Arnhard, A. Gottschall, F. Pitterl, H. Oberacher, Applying 'Sequential Windowed Acquisition of All
386 Theoretical Fragment Ion Mass Spectra' (SWATH) for systematic toxicological analysis with liquid
387 chromatography-high-resolution tandem mass spectrometry, *Anal Bioanal Chem*, 407 (2015) 405-414.
- 388 [45] T. Bruderer, E. Varesio, A.O. Hidasi, E. Duchoslav, L. Burton, R. Bonner, G. Hopfgartner, Metabolomic
389 spectral libraries for data-independent SWATH liquid chromatography mass spectrometry acquisition, *Anal*
390 *Bioanal Chem*, 410 (2018) 1873-1884.
- 391 [46] S. Sidoli, R. Fujiwara, B.A. Garcia, Multiplexed data independent acquisition (MSX-DIA) applied by high
392 resolution mass spectrometry improves quantification quality for the analysis of histone peptides, *Proteomics*, 16
393 (2016) 2095-2105.
- 394 [47] A.T. Roemmelt, A.E. Steuer, M. Poetzsch, T. Kraemer, Liquid chromatography, in combination with a
395 quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical
396 fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic
397 toxicology and comparison with information-dependent acquisition (IDA), *Anal Chem*, 86 (2014) 11742-11749.

- 398 [48] A. Bilbao, E. Varesio, J. Luban, C. Strambio-De-Castillia, G. Hopfgartner, M. Muller, F. Lisacek,
399 Processing strategies and software solutions for data-independent acquisition in mass spectrometry, *Proteomics*,
400 15 (2015) 964-980.
- 401 [49] X. Zhu, Y. Chen, R. Subramanian, Comparison of information-dependent acquisition, SWATH, and
402 MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-
403 quadrupole time-of-flight mass spectrometry, *Anal Chem*, 86 (2014) 1202-1209.

404

405 Tables:

Table 1: List of the 30 substances used for the method evaluation with their respective limits of identification (LOIs), limits of detection (LODs) and therapeutic ranges or legal thresholds. Matrix effect (ME) and recovery (RE) were evaluated at two concentration levels (20 and 200 ng mL⁻¹) on those substances involving a representative panel of the classes of the molecules of interest.

Substance	LOI (ng mL ⁻¹)	LOD (ng mL ⁻¹)	RE (CV) (20 ng mL ⁻¹)	ME (CV) (20 ng mL ⁻¹)	RE (CV) (200 ng mL ⁻¹)	ME (CV) (200 ng mL ⁻¹)	Therapeutic range/ Legal threshold (ng mL ⁻¹)
6-MAM	5	1	90% (6%)	5% (7%)	57% (19%)	-5% (3%)	-
Aminoclonazepam	10	10	72% (10%)	-27% (4%)	41% (10%)	-19% (5%)	-
Amitryptiline	1	< 1	94% (10%)	208% (23%)	46% (20%)	100% (12%)	50-300
Amphetamine	10	1	49% (5%)	-5% (7%)	25% (5%)	48% (4%)	15
Benzoylecgonine	1	< 1	36% (5%)	-16% (5%)	24% (6%)	-8% (2%)	-
Benzylpiperazine	1	< 1	88% (5%)	-3% (8%)	38% (27%)	-16% (5%)	-
Butylone	1	< 1	65% (5%)	-4% (7%)	30% (24%)	-5% (5%)	-
Carbamezapine	1	< 1	89% (4%)	-18% (4%)	55% (10%)	-10% (3%)	200-800
Citalopram	1	< 1	110% (10%)	31% (18%)	61% (17%)	-14% (11%)	50-110
Cocaine	1	< 1	121% (5%)	29% (9%)	60% (11%)	-2% (7%)	15
Codeine	5	1	72% (6%)	-5% (5%)	52% (8%)	-3% (2%)	30-250
Diazepam	1	< 1	88% (8%)	-20% (7%)	47% (7%)	-16% (2%)	100-2000
Fluoxetine	1	< 1	113% (19%)	319% (28%)	71% (19%)	178% (10%)	120-500
Gabapentin	20	5	57% (15%)	-35% (42%)	39% (6%)	-22% (21%)	50-600
Haloperidol	1	< 1	106% (19%)	170% (19%)	57% (19%)	114% (11%)	5-17
Hydroxymidazolam	1	< 1	90% (8%)	-28% (4%)	49% (15%)	-23% (4%)	-
Ketamine	5	1	71% (2%)	6% (7%)	34% (13%)	-3% (3%)	1000-6000
MDMA	1	< 1	68% (3%)	-9% (6%)	33% (34%)	-9% (5%)	15
Methadone	1	< 1	99% (11%)	21% (21%)	48% (21%)	-15% (9%)	100-500
Methamphetamine	1	< 1	49% (5%)	-10% (8%)	22% (6%)	-13% (4%)	15
Methedrone	1	< 1	68% (3%)	-9% (6%)	33% (34%)	-9% (5%)	-
Methylone	1	< 1	58% (4%)	-17% (9%)	25% (31%)	-17% (4%)	-
Mianserin	1	< 1	84% (6%)	122% (16%)	37% (17%)	36% (9%)	15-70
Midazolam	1	< 1	73% (7%)	-18% (3%)	51% (9%)	-11% (3%)	40-100
Morphine	10	5	56% (5%)	-10% (4%)	19% (41%)	38% (9%)	15 (free form)
Quetiapine	1	< 1	98% (3%)	85% (7%)	57% (13%)	31% (3%)	100-500
Risperidone	1	< 1	107% (11%)	111% (16%)	57% (19%)	30% (10%)	6-20
THC-COOH	10	5	49% (6%)	-53% (6%)	28% (16%)	-41% (6%)	-
Trimipramine	5	1	89% (14%)	166% (26%)	43% (17%)	66% (15%)	10-30
Zolpidem	1	< 1	90% (7%)	32% (4%)	51% (7%)	9% (4%)	80-150

406

407

408

409

410

411

412


413

414

415


416 Figures:

417 **Figure 1:** 104 real cases have been analyzed by the developed method and two other routine methods. The Venn
418 diagram represents the percentage of identification performed by each method (A). The results were confirmed
419 by quantitative analysis of the substances targeted by all 3 methods. The percentage of identification not
420 performed by the routine approaches is represented depending on the concentration (B).



421
422

423 **Figure 2:** The case apparition percentage in the 104 real cases is represented by bar charts.



424

Highlights:

- First study on the application of dried blood spot (DBS) microsampling hyphenated with LC and Orbitrap technology for clinical and forensic toxicology screening
- Minimal blood volume requirement for powerful screening and identification using high resolution MS.
- Validation of the developed method according to guidelines for qualitative approaches and assessment using 104 real cases analysed by reference approaches.
- Great relevance for practice in clinical and forensic toxicology opening new opportunities towards friendly sampling process in non-medical environments.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: